Kazia Therapeutics (KZIA) has released an update.
Kazia Therapeutics has successfully regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This compliance was achieved after the company’s American Depositary Shares consistently closed at $1.00 or higher for 10 consecutive days. Investors may view this as a positive sign for the company’s market stability and future prospects.
For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.
